Ascentifi is a company that facilitates lifescience investing by providing access to investment opportunities in the sector.

Ascentifi

Our mission is to make investment in Lifescience companies accessible & straightforward for everyone. 

Our core value proposition is our ability to source investment opportunities then arrange all aspects of the investment. 

Our clients get access to opportunities usually not publicly known or accessible, being the preserve of specialised Venture Capital firms and inner circle investors.

Our investors get to focus on making investment decisions instead of burning countless hours trying to find accessible opportunities and deal with investment related administration. 

Additionally, we stay connected for the lifetime of the investment, sharing progress updates from the Company, collating shareholder decisions, and working through any exit process to (hopefully) realise a return. 

Visit our Website for more information, and register to receive a notification every time we have an investment opportunity available. Registration creates no obligation to invest - that decision is entirely up to you every time. 

Congrats to our latest portfolio company - VertiGenius have successfully closed a €2.1m investment round to fuel business expansion & further development of their innovative vertigo technology. 

#Vertigenius #Atlanticbridge #Ascentifi #Medtech #Vertigo

A recent article in The Currency citing Elkstone as keen to do more investments in MedTech start-ups caught our eye.

It’s just over a year since Elkstone closed their €100 million early-stage investment fund for start-ups. They already have skin in the MedTech game, so they understand the unique challenges associated with MedTech investing, and they understand the potential rewards for all that effort. 

What resonated with the Ascentifi watercooler Illuminati was how the Elkstone view on opportunities in the MedTech space aligns with our own. Their desire to continue investing in the space surely serves as further validation of the opportunities it presents.

The key is filtering out the few great start-ups from the muddled mediocre. This requires deep MedTech domain knowledge and lots of time. It also helps to be plugged into the ecosystem - the best deals are usually not “shopped around” - and you’ll need a large enough cheque to get a seat at the table when the round closes.

If you’re interested in seeing MedTech investment opportunities and prefer to invest modest amounts on a deal-by-deal basis without countless hours of research or committing to an investment fund, then Ascentifi can help.

Resister your interest on our website and we’ll be in touch to explain how.  
https://ascentifi.com/

(The article in The Currency is here : https://lnkd.in/e3vczMuy)

#MedTech #ElkStone #TheCurrency

Congratulations to our portfilio company CroiValve who recently announced positive clinical outcomes from their TANDEM I trial of the CroiValve DUO heart valve system for treatment of Tricuspid Regurgitation (TR).

The results were presented at New York Valves 2024, a highly prestigious summit dedicated to reshaping innovation and fostering collaboration in the field of valvular and structural heart disease.

The DUO System is a novel transcatheter coaptation valve that works in tandem with the native tricuspid valve to restore valve function, using an anchor system which leaves the right heart and native valve apparatus untouched.

Results demonstrated significant TR reduction, as well as markedly improved functional and Quality of Life outcomes. These findings represent promising advancements in the treatment of TR with the DUO system. 

Read more in their latest latest press : https://t.ly/szd7Z

#Croivalve #Ascentifi #MedTech #Heart

Some positive news for investors in todays #Budget2024. 
#EIIS #investment
https://lnkd.in/eVF6TXpy

Sign Up Today: https://lnkd.in/eVF6TXpy
If the prospect of reducing your Income Tax bill by 40% with the EII Scheme has piqued your interest in investing, here are a few reasons why adding LifeScience startups to your portfolio can be a compelling choice.

#eiis #lifescience #startups #investing

Significant milestones for our portfolio company CroiValve on their mission to improve Quality of Life for millions of people suffering from heart disease:

(1) Regulatory approval in the United States for a large clinical trial of their highly innovative DUO Tricuspid Valve Repair System

(2) World renowned interventional cardiologist Dr. Marty B Leon joins as chair of their Clinical Advisory Board.

Well done Lucy O'Keefe and Team - We're all proud of you.

#croivalve #ascentifi #medtech #ireland

Metric
Company Name	Ascentifi
Symbol
MSH ID	COM:ASCENTIFI
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Investment Management
Country	US
Stage
Employee Count	3
Website	ascentifi.com
LinkedIn	ascentifi
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ASCE

COM:ASCENTIFI

Ascentifi

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue